Stocks · News reference
TD Cowen Maintains Buy Rating and Increases Price Target for United Therapeutics
TD Cowen has maintained a 'Buy' rating on United Therapeutics Corporation and raised its price target to $700 from $675.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Raises Price Target on United Therapeutics to $725
RBC Capital Markets increased its price target for United Therapeutics Corporation from $697 to $725 while maintaining an Outperform rating.
United Therapeutics Announces Acquisition of Pfizer Royalty Interest in Ralinepag
United Therapeutics has agreed to pay $525 million to eliminate its future royalty obligations to Pfizer related to the experimental lung disease therapy ralinepag.
BTIG Raises Price Target on United Therapeutics
BTIG maintained a Buy rating on United Therapeutics and increased its price target from $728 to $768.
United Therapeutics Reports Third Quarter 2026 Financial Results
United Therapeutics Corporation announced its financial results for the third quarter of 2026, highlighting record revenue performance and a positive growth outlook.
United Therapeutics Announces New $2 Billion Share Repurchase Authorization
Alongside its third-quarter financial results, United Therapeutics Corporation announced a new $2 billion share repurchase authorization.